BackNewAmsterdam Pharma Company NV Overview

NewAmsterdam Pharma Company NV Other Assets

Track NewAmsterdam Pharma Company NV's other assets ($0) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Other Assets
$0.00

Peer trimmed avg / median

Loading

NewAmsterdam Pharma Company NV Other Assets History

Loading

NewAmsterdam Pharma Company NV vs. peers: Other Assets Comparison

Loading

NewAmsterdam Pharma Company NV Other Assets Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

NewAmsterdam Pharma Company NV (NAMS) FAQ

The latest other assets for NAMS is $0 as of June 2026. In the prior-year period, the figure was $0. Investors often review this figure alongside NewAmsterdam Pharma Company NV's historical trend and sector peers before judging valuation or financial health.

Over the past year, NAMS's other assets moved from $0 to $0. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in NewAmsterdam Pharma Company NV's operating scale or balance-sheet position.

A other assets figure of $0 for NAMS is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting NAMS's other assets ($0), review year-over-year change from $0, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.